Xuan Wang,Haiyun Zhang,Xiaozhuo Chen
Xuan Wang
Cancer is the second leading cause of death in the US. Current major treatments for cancer management include surgery, cytotoxic chemotherapy, targeted therapy, radiation therapy, endocrine therapy and immunotherapy. Despite the endeavors a...
Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance? [0.03%]
FDA批准的蛋白酶体抑制剂适应性是否是药物耐药性的潜在机制？
Kyung Bo Kim
Kyung Bo Kim
With proteasome inhibitors (PIs) becoming clinically available since 2003, outcomes for patients with multiple myeloma (MM) have dramatically changed, improving quality of life and survival. Despite the impressive treatment success, however...
ATP-binding cassette transporters at the zebrafish blood-brain barrier and the potential utility of the zebrafish as an in vivo model [0.03%]
应用于斑马鱼血脑屏障的ATP结合盒式运输蛋白及利用斑马鱼进行活体研究的潜在价值
Jordan M Hotz,Joanna R Thomas,Emily N Katz et al.
Jordan M Hotz et al.
The brain is protected from toxins by a tightly regulated network of specialized cells, including endothelial cells, pericytes, astrocyes, and neurons, known collectively as the blood-brain barrier (BBB). This selectively permeable barrier ...
Key genes and drug delivery systems to improve the efficiency of chemotherapy [0.03%]
提高化疗效率的关键基因和药物递送系统
Zally Torres-Martinez,Yamixa Delgado,Yancy Ferrer-Acosta et al.
Zally Torres-Martinez et al.
Cancer cells can develop resistance to anticancer drugs, thereby becoming tolerant to treatment through different mechanisms. The biological mechanisms leading to the generation of anticancer treatment resistance include alterations in tran...
Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia [0.03%]
抗VEENETOCLAX和低甲基化药物的急性髓系白血病ripsi resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
Antoine N Saliba,August J John,Scott H Kaufmann
Antoine N Saliba
Despite the success of the combination of venetoclax with the hypomethylating agents (HMA) decitabine or azacitidine in inducing remission in older, previously untreated patients with acute myeloid leukemia (AML), resistance - primary or se...
Cell-mediated and cell membrane-coated nanoparticles for drug delivery and cancer therapy [0.03%]
用于药物递送和癌症治疗的细胞介导和细胞膜包被的纳米颗粒
Serkan Yaman,Uday Chintapula,Edgar Rodriguez et al.
Serkan Yaman et al.
Nanotechnology-based drug delivery platforms have been developed over the last two decades because of their favorable features in terms of improved drug bioavailability and stability. Despite recent advancement in nanotechnology platforms, ...
Richa Rathore,Charles R Schutt,Brian A Van Tine
Richa Rathore
At the forefront of cancer research is the rapidly evolving understanding of metabolic reprogramming within cancer cells. The expeditious adaptation to metabolic inhibition allows cells to evolve and acquire resistance to targeted treatment...
MicroRNAs in treatment-induced neuroendocrine differentiation in prostate cancer [0.03%]
治疗引起的前列腺癌神经内分泌分化中的微小核糖核酸
Theresa Akoto,Divya Bhagirath,Sharanjot Saini
Theresa Akoto
Prostate cancer is a condition commonly associated with men worldwide. Androgen deprivation therapy remains one of the targeted therapies. However, after some years, there is biochemical recurrence and metastatic progression into castration...
Nitric oxide-elicited resistance to anti-glioblastoma photodynamic therapy [0.03%]
一氧化氮引发的对胶质母细胞瘤光动力疗法的抗性
Albert W Girotti,Jonathan M Fahey,Witold Korytowski
Albert W Girotti
Glioblastoma multiforme is a highly aggressive primary brain malignancy that resists most conventional chemoand radiotherapeutic interventions. Nitric oxide (NO), a short lived free radical molecule produced by inducible NO synthase (iNOS) ...
Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma [0.03%]
胰腺导管腺癌Gemcitabine耐药类患者源性异种移植模型的建立
Aubrey L Miller,Patrick L Garcia,Tracy L Gamblin et al.
Aubrey L Miller et al.
Aim: Gemcitabine is a frontline agent for locally-advanced and metastatic pancreatic ductal adenocarcinoma (PDAC), but neither gemcitabine alone nor in combination produces durable remissions of this tumor type. We develo...